Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the company’s stock, valued at approximately $237,000.
Several other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC boosted its position in shares of 10x Genomics by 2.7% during the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock worth $301,849,000 after purchasing an additional 357,470 shares during the period. ARK Investment Management LLC boosted its position in shares of 10x Genomics by 15.4% during the third quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock worth $242,743,000 after buying an additional 1,436,582 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of 10x Genomics by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock valued at $143,907,000 after buying an additional 230,145 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of 10x Genomics in the 4th quarter valued at $26,308,000. Finally, Geode Capital Management LLC lifted its stake in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock worth $41,009,000 after acquiring an additional 42,777 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.
10x Genomics Price Performance
Shares of NASDAQ:TXG opened at $14.84 on Thursday. 10x Genomics, Inc. has a 12 month low of $12.95 and a 12 month high of $51.22. The firm has a market capitalization of $1.80 billion, a P/E ratio of -9.70 and a beta of 1.83. The company’s fifty day moving average price is $15.11 and its 200 day moving average price is $17.80.
Analysts Set New Price Targets
A number of analysts have issued reports on TXG shares. Stephens reiterated an “overweight” rating and set a $30.00 price target on shares of 10x Genomics in a research note on Thursday, October 10th. Barclays cut their price target on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Canaccord Genuity Group decreased their price objective on 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, October 10th. Citigroup cut their target price on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, October 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, January 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $23.86.
View Our Latest Research Report on 10x Genomics
10x Genomics Profile
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Stories
- Five stocks we like better than 10x Genomics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- 3 REITs to Buy and Hold for the Long Term
- 3 Steel Stocks Soaring After Tariff Announcements
- Which Wall Street Analysts are the Most Accurate?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG – Free Report).
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.